Companies

Mind Medicine Inc

NASDAQ: MNMD
$0.69
▼ $0.02 (−3.40%) today
Markets closed · 4:57pm ET

About MindMed

Definium Therapeutics, Inc. (NASDAQ: DFTX) is a pre-revenue, late-stage clinical biopharmaceutical company developing psychedelic-derived therapeutics intended to address underlying causes of psychiatric and neurological disorders.

Its lead candidate, DT120 ODT, is a proprietary, pharmaceutically optimized orally disintegrating tablet of lysergide (LSD) tartrate. It acts as a partial agonist at 5-HT2A receptors and uses Catalent's Zydis fast-dissolve technology.
- **GAD:** positive results from three Phase 3 studies in GAD and MDD (Voyage, Panorama and Emerge), with an NDA filing targeted for the first half of 2027.
- **MDD:** the Phase 3 Ascend study is enrolling.
- **PTSD:** the Phase 3 Haven study is planned for 2027.
- DT120 holds FDA Breakthrough Therapy designation in both GAD and MDD.

The second program, DT402, is a proprietary R(-)-MDMA enantiomer being developed for core symptoms of autism spectrum disorder. It showed positive initial Phase 2a results.

The company is building commercial-readiness capabilities ahead of a potential launch. Any launch would depend on FDA approval and DEA/state rescheduling of Schedule I substances. Definium held approximately $1.05 billion in cash, cash equivalents and investments, which it expects to fund operations into 2030. Updated

MNMD Coverage

Frequently Asked Questions

What does MindMed do?

Definium Therapeutics, Inc. (NASDAQ: DFTX) is a pre-revenue, late-stage clinical biopharmaceutical company developing psychedelic-derived therapeutics intended to address underlying causes of psychiatric and neurological disorders.